Trans-scleral delivery of macromolecules

Therapeutic Delivery

Volumn 2, Issue 10, 2011, Pages 1331-1349

  Pescina, Silvia ^a   Santi, Patrizia ^a   Ferrari, Giulio ^b   Nicoli, Sara ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APTAMER; BEVACIZUMAB; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; DNA; ETANERCEPT; EYE DROPS; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GAMMA INTERFERON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 10; INULIN; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; OLIGONUCLEOTIDE; PEGAPTANIB; PEPTIDE; PIGMENT EPITHELIUM DERIVED FACTOR; POLYNUCLEOTIDE; PROTEIN; RANIBIZUMAB; RITUXIMAB; RNA; SMALL INTERFERING RNA; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VASOACTIVE INTESTINAL POLYPEPTIDE;

DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG INSTILLATION; DRUG PENETRATION; DRUG RELEASE; GLAUCOMA; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LYMPHOMA; MACROMOLECULE; MOLECULAR WEIGHT; NON INVASIVE PROCEDURE; NONHUMAN; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; REVIEW; SCREENING TEST; SUBRETINAL NEOVASCULARIZATION; TRANS SCLERAL DRUG ADMINISTRATION; UVEITIS; VIRUS INFECTION;

EID: 80054118834     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.104     Document Type: Review

References (132)

1. Resnikoff S, Pascolini D, Etya'ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844-851 (2004) (Pubitemid 39573742)
2. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr. Opin. Ophthalmol. 21, 178-183 (2010)
3. Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis. 13, 1783-1792 (2007) (Pubitemid 47497006)
4. Bourges JL, Bloquel C. Thomas A et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Delivery Rev. 58, 1182-1202 (2006) (Pubitemid 44794429)
5. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J. Pharm. Sci. 99, 2219-2239 (2010)
6. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev. 58, 1164-1181 (2006)
7. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 1, 99-114 (2004) (Pubitemid 40297959)
8. Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug Discov. Today 16, 270-277 (2011)
9. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today 13, 135-143 (2008)
10. Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm. Res. 27, 530-543 (2010)
11. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 12, 348-360 (2010)
12. Kuppermann BD, Loewenstein A. Drug delivery to the posterior segment of the eye. Dev. Ophthalmol. 47, 59-72 (2010)
13. Kearns VR, Williams RL. Drug delivery systems for the eye. Expert Rev. Med. Devices 6, 277-290 (2009)
14. Barocas VH, Balachandran RK. Sustained transscleral drug delivery. Expert Opin. Drug Deliv. 5, 1-10 (2008) (Pubitemid 351234106)
15. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 39, 244-254 (2007) (Pubitemid 47557244)
16. Anderson OA, Bainbridge JW, Shima DT. Delivery of anti-angiogenic molecular therapies for retinal disease. Drug Discov. Today 15, 272-282 (2010)
17. Lambiase A, Aloe L, Centofanti M et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc. Natl Acad. Sci. USA 106, 13469-13474 (2009)
18. Zhang K, Hopkins JJ, Heier JS et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc. Natl Acad. Sci. USA 108, 6241-6245 (2011)
19. El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog. Retinal Eye Res. 29, 443-465 (2010)
20. Fattal E, Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 58, 1203-1223 (2006)
21. Mandel M. Some Properties of Polyelectrolyte Solutions and the Scaling Approach. Marcel Dekker, NY, USA (1993)
22. Wang L, Yu H. Chain conformation of linear polyelectrolyte in salt solutions: sodium poly(styrene sulfonate) in potassium chloride and sodium chloride solutions. Macromolecules 21, 3498-3501 (1988)
23. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug. Chem. 21(12), 2153-2163 (2010)
24. Hayakawa E, Chien DS, Inagaki K, Yamamoto A, Wang W, Lee VH. Conjunctival penetration of insulin and peptide drugs in the albino rabbit. Pharm. Res. 9, 769-775 (1992)
25. Hosoya K, Lee VH, Kim KJ. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur. J. Pharm. Biopharm. 60, 227-240 (2005) (Pubitemid 40804563)
26. Sasaki H, Yamamura K, Mukai T et al. Modification of ocular permeability of peptide drugs by absorption promoters. Biol. Pharm. Bull. 23, 1524-1527 (2000) (Pubitemid 32016323)
27. Sasaki H, Yamamura K, Tei C, Nishida K, Nakamura J. Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. J. Drug Target. 3, 129-135 (1995)
28. Horibe Y, Hosoya K, Kim KJ, Ogiso T, Lee VH. Polar solute transport across the pigmented rabbit conjunctiva: size dependence and the influence of 8-bromo cyclic adenosine monophosphate. Pharm. Res. 14, 1246-1251 (1997) (Pubitemid 27432551)
29. Nomoto H, Shiraga F, Kuno N et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 50, 4807-4813 (2009)
30. Hagigit T, Abdulrazik M, Orucov F et al. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J. Control. Release 145, 297-305 (2010)
31. Furrer E, Berdugo M, Stella C et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-a single-chain antibody, upon topical administration to the rabbit eye. Invest. Ophthalmol. Vis. Sci. 50, 771-778 (2009)
32. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration of topical anti-TNF-a single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest. Ophthalmol. Vis. Sci. 50, 779-786 (2009)
33. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug deliveryInvest. Ophthalmol. Vis. Sci. 26, 584-587 (1985) (Pubitemid 15059025)
34. Kim TW, Lindsey JD, Aihara M, Anthony TL, Weinreb RN. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci. 43, 1809-1816 (2002) (Pubitemid 34587025)
35. Li J, Wasmuth S, Bauer D, Baehler H, Hennig M, Heiligenhaus A. Subconjunctival antisense oligonucleotides targeting TNF-a influence immunopathology and viral replication in murine HSV-1 retinitis. Graefes Arch. Clin. Exp. Ophthalmol. 246, 1265-1273 (2008)
36. Gehlbach P, Demetriades AM, Yamamoto S et al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. 10, 637-646 (2003) (Pubitemid 36553609)
37. Kim SH, Csaky KG, Wang NS, Lutz RJ. Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm. Res. 25, 512-520 (2008) (Pubitemid 351357728)
38. Edwards A, Prausnitz MR. Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. AIChE J. 44, 214-225 (1998) (Pubitemid 128485306)
39. Boubriak OA, Urban JP, Akhtar S, Meek KM, Bron AJ. The effect of hydration and matrix composition on solute diffusion in rabbit sclera. Exp. Eye Res. 71, 503-514 (2000)
40. Maurice DM, Polgar J. Diffusion across the sclera. Exp. Eye Res. 25, 577-582 (1977) (Pubitemid 8246490)
41. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Vis. Sci. 36, 1893-1903 (1995)
42. Ambati J, Canakis CS, Miller JW et al. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Vis. Sci. 41, 1181-1185 (2000) (Pubitemid 30187558)
43. Kadam RS, Cheruvu NP, Edelhauser HF, Kompella UB. Sclera-choroid-RPE transport of eight b-blockers in human, bovine, porcine, rabbit, and rat models. Invest. Ophthalmol. Vis. Sci. 52(8), 5387-5399 (2011)
44. Nicoli S, Ferrari G, Quarta M et al. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability. Mol. Vis. 15, 259-266 (2009)
45. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87, 1479-1488 (1998)
46. Macchioni A, Ciancaleoni G, Zuccaccia C, Zuccaccia D. Determining accurate molecular sizes in solution through NMR diffusion spectroscopy. Chem. Soc. Rev. 37, 479-489 (2008)
47. Wen H, Hao J, Li SK. Influence of permeant lipophilicity on permeation across human sclera. Pharm. Res. 27, 2446-2456 (2010)
48. Kadam RS, Kompella UB. Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J. Pharmacol. Exp. Ther. 332, 1107-1120 (2010)
49. Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab. Dispos. 39, 771-781 (2011)
50. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest. Ophthalmol. Vis. Sci. 47, 4513-4522 (2006) (Pubitemid 46579380)
51. Lin CW, Wang Y, Challa P, Epstein DL, Yuan F. Transscleral diffusion of ethacrynic acid and sodium fluorescein. Mol. Vis. 13, 243-251 (2007) (Pubitemid 46323082)
52. Ranta VP, Mannermaa E, Lummepuro K et al. Barrier analysis of periocular drug delivery to the posterior segment. J. Control. Release 148(1) 42-48 (2010)
53. Gyenge CC, Tenstad O, Wiig H. In vivo determination of steric and electrostatic exclusion of albumin in rat skin and skeletal muscle. J. Physiol. 552, 907-916 (2003) (Pubitemid 37428429)
54. Taylor AE, Parker JC. Intersitial exluded volumes: the effect of charge. J. Physiol. 553, 333 (2003) (Pubitemid 37527537)
55. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co- glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci. 44, 290-299 (2003) (Pubitemid 36134287)
56. Alberdi E, Hyde CC, Becerra SP. Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site. Biochemistry 37, 10643-10652 (1998) (Pubitemid 28357865)
57. Waldbillig RJ, Arnold DR, Fletcher RT, Chader GJ. Insulin and IGF-1 binding in chick sclera. Invest. Ophthalmol. Vis. Sci. 31, 1015-1022 (1990) (Pubitemid 20197623)
58. Hussain AA, Starita C, Hodgetts A, Marshall J. Macromolecular diffusion characteristics of ageing human Bruch's membrane: implications for age-related macular degeneration (AMD)Exp. Eye Res. 90, 703-710 (2010)
59. Bernstein MH, Hollenberg MJ. Fine structure of the choriocapillaris and retinal capillaries. Invest. Ophthalmol. Vis. Sci. 4, 1016-1025 (1965)
60. Starita C, Hussain AA, Patmore A, Marshall J. Localization of the site of major resistance to fluid transport in Bruch's membrane. Invest. Ophthalmol. Vis. Sci. 38, 762-767 (1997) (Pubitemid 27143147)
61. Moore DJ, Clover GM. The effect of age on the macromolecular permeability of human Bruch's membrane. Invest. Ophthalmol. Vis. Sci. 42, 2970-2975 (2001) (Pubitemid 33035298)
62. Pitkanen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 46, 641-646 (2005) (Pubitemid 40270347)
63. Pescina S, Padula C, Santi P, Nicoli S. Effect of formulation factors on the trans-scleral iontophoretic and post-iontophoretic transport of a 40 kDa dextran in-vitro. Eur. J. Pharm. Sci. 42, 503-508 (2011)
64. Amrite A, Pugazhenthi V, Cheruvu N, Kompella U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert. Opin. Drug Deliv. 7, 631-645 (2010)
65. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 49, 333-341 (2008)
66. Pitkanen L, Ranta VP, Moilanen H, Urtti A. Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium. Pharm. Res. 24, 2063-2070 (2007) (Pubitemid 47493576)
67. Geng J, Yuan P, Shao C et al. Bacterial melanin interacts with double-stranded DNA with high affinity and may inhibit cell metabolism in vivo. Arch. Microbiol. 192, 321-329 (2010)
68. Eckhart L, Bach J, Ban J, Tschachler E. Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem. Biophys. Res. Commun. 271, 726-730 (2000) (Pubitemid 30444696)
69. Chan JE, Pridgen TA, Csaky KG. Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat. Exp. Eye Res. 90, 501-506 (2010)
70. Robinson MR, Lee SS, Kim H et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 82, 479-487 (2006) (Pubitemid 43138962)
71. Spitznas M, Reale E. Fracture faces of fenestrations and junctions of endothelial cells in human choroidal vessels. Invest. Ophthalmol. Vis. Sci. 14, 98-107 (1975)
72. Rieke ER, Amaral J, Becerra SP, Lutz RJ. Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J. Ocul. Pharmacol. Ther. 26, 55-64 (2010)
73. Steuer H, Jaworski A, Stoll D, Schlosshauer B. In vitro model of the outer blood-retina barrier. Brain Res. Brain Res. Protoc. 13, 26-36 (2004) (Pubitemid 38519596)
74. Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. 60, 207-225 (2005) (Pubitemid 40804562)
75. Mannermaa E, Reinisalo M, Ranta VP et al. Filter-cultured ARPE-19 cells as outer blood- retinal barrier model. Eur. J. Pharm. Sci. 40, 289-296 (2010)
76. Mannermaa E, Vellonen KS, Ryhanen T et al. Efflux protein expression in human retinal pigment epithelium cell lines. Pharm. Res. 26, 1785-1791 (2009)
77. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood- retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev. 58, 1136-1163 (2006)
78. Amaral J, Fariss RN, Campos MM et al. Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. Invest. Ophthalmol. Vis. Sci. 46, 4383-4392 (2005) (Pubitemid 44264530)
79. Mac Gabhann F, Demetriades AM, Deering T et al. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann. Biomed. Eng. 35, 615-630 (2007) (Pubitemid 46448166)
80. Ban Y, Rizzolo LJ. A culture model of development reveals multiple properties of RPE tight junctions. Mol. Vis. 3, 18 (1997)
81. Anderson OA, Jackson TL, Singh JK, Hussain AA, Marshall J. Human transscleral albumin permeability and the effect of topographical location and donor age. Invest. Ophthalmol. Vis. Sci. 49, 4041-4045 (2008)
82. Chiang A, Haller JA. Vitreoretinal disease in the coming decade. Curr. Opin. Ophthalmol. 21, 197-202 (2010)
83. Conway BR. Recent patents on ocular drug delivery systems. Recent Pat. Drug Deliv. Formul. 2, 1-8 (2008) (Pubitemid 351546429)
84. Srivastava R, Pathak K. An updated patent review on ocular drug delivery systems with potential for commercial viability. Recent Pat. Drug Deliv. Formul. 5, 146-162 (2011)
85. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 29, 596-609 (2010)
86. Bochot A, Lajavardi L, Camelo S et al. Potential of liposomes for the intravitreal injection of therapeutic molecules. Ann. Pharm. Fr. 69, 100-107 (2011)
87. Tamboli V, Mishra GP, Mitra AK. Polymeric vectors for ocular gene delivery. Therapeutic Delivery 2, 523-536 (2011)
88. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Therapeutic Delivery 1, 435-456 (2010)
89. Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J. Control. Release 136, 247-253 (2009)
90. Tsui JY, Dalgard C, Van Quill KR et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest. Ophthalmol. Vis. Sci. 49, 490-496 (2008)
91. Simpson AE, Gilbert JA, Rudnick DE et al. Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch. Ophthalmol. 120, 1069-1074 (2002) (Pubitemid 34856075)
92. Van Quill KR, Dioguardi PK, Tong CT et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112, 1151-1158 (2005) (Pubitemid 40797475)
93. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol. 57, 1555-1563 (2005) (Pubitemid 41752269)
94. Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans. Am. Ophthalmol. Soc. 106, 206-213; discussion 213-214 (2008)
95. Misra GP, Singh RS, Aleman TS, Jacobson SG, Gardner TW, Lowe TL. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials 30, 6541-6547 (2009)
96. Ambati J, Gragoudas ES, Miller JW et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Vis. Sci. 41, 1186-1191 (2000) (Pubitemid 30187559)
97. Kawashima T, Nagai N, Kaji H et al. A scalable controlled-release device for transscleral drug delivery to the retina Biomaterials 32, 1950-1956 (2011)
98. Jorgensen L, Nielson HM. Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines. John Wiley & Sons Ltd, Chichester, UK (2010)
99. Jiang J, Gill HS, Ghate D et al. Coated microneedles for drug delivery to the eye. Invest. Ophthalmol. Vis. Sci. 48, 4038-4043 (2007) (Pubitemid 351261027)
100. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm. Res. 26, 395-403 (2009)
101. Patel SR, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res. 28, 166-176 (2011)
102. Mitragotri S, Kost J. Low-frequency sonophoresis: a noninvasive method of drug delivery and diagnostics. Biotechnol. Prog. 16, 488-492 (2000) (Pubitemid 30369022)
103. Lavon I, Kost J. Ultrasound and transdermal drug delivery. Drug Discov. Today 9, 670-676 (2004). (Pubitemid 38981721)
104. Cheung AC, Yu Y, Tay D, Wong HS, Ellis-Behnke R, Chau Y. Ultrasound-enhanced intrascleral delivery of protein. Int. J. Pharm. 401, 16-24 (2010)
105. Luzardo-Alvarez A, Rodriguez-Fernandez M, Blanco-Mendez J, Guy RH, Delgado-Charro MB. Iontophoretic permselectivity of mammalian skin: characterization of hairless mouse and porcine membrane models. Pharm. Res. 15, 984-987 (1998) (Pubitemid 28356911)
106. Fisher GA, Parkinson TM, Szlek MA. Ocuphor-the future of ocular drug delivery. Drug Deliv. Tech. 2, 50-52 (2002)
107. Parkinson TM, Ferguson E, Febbraro S, Bakhtyari A, King M, Mundasad M. Tolerance of ocular iontophoresis in healthy volunteers. J. Ocul. Pharmacol. Ther. 19, 145-151 (2003) (Pubitemid 36539140)
108. Vollmer DL, Szlek MA, Kolb K, Lloyd LB, Parkinson TM. In vivo transscleral iontophoresis of amikacin to rabbit eyes. J. Ocul. Pharmacol. Ther. 18, 549-558 (2002) (Pubitemid 36020256)
109. Eljarrat-Binstock E, Domb AJ, Orucov F, Dagan A, Frucht-Pery J, Pe'er J. In vitro and in vivo evaluation of carboplatin delivery to the eye using hydrogel-iontophoresis. Curr. Eye Res. 33, 269-275 (2008)
110. Eljarrat-Binstock E, Domb AJ, Orucov F, Frucht-Pery J, Pe'er J. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr. Eye Res. 32, 639-646 (2007) (Pubitemid 47400678)
111. Gungor S, Delgado-Charro MB, Ruiz-Perez B et al. Trans-scleral iontophoretic delivery of low molecular weight therapeutics. J. Control. Release 147, 225-231 (2010)
112. Behar-Cohen FF, El Aouni A et al. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp. Eye Res. 74, 51-59 (2002) (Pubitemid 34948265)
113. Voigt M, Kralinger M, Kieselbach G et al. Ocular aspirin distribution: a comparison of intravenous, topical and Coulomb-controlled iontophoresis administration. Invest. Ophthalmol. Vis. Sci. 43, 3299-3306 (2002)
114. Nicoli S, Ferrari G, Quarta M, Macaluso C, Santi P. In vitro transscleral iontophoresis of high molecular weight neutral compounds. Eur. J. Pharm. Sci. 36, 486-492 (2009)
115. Chopra P, Hao J, Li SK. Iontophoretic transport of charged macromolecules across human sclera. Int. J. Pharm. 388, 107-113 (2010)
116. Pescina S, Ferrari G, Govoni P, Macaluso C et al. In vitro permeation of bevacizumab through human sclera: effect of iontophoresis application. J. Pharm. Pharmacol. 62, 1189-1194 (2010)
117. Davies JB, Ciavatta VT, Boatright JH, Nickerson JM. Delivery of several forms of DNA, DNA-RNA hybrids, and dyes across human sclera by electrical fields. Mol. Vis. 15, 569-578 (2003) (Pubitemid 38097624)
118. Asahara T, Shinomiya K, Naito T, Shiota H. Induction of gene into the rabbit eye by iontophoresis: preliminary report. Jpn J. Ophthalmol. 45, 31-39 (2001) (Pubitemid 32015891)
119. Voigt M, de Kozak Y, Halhal M, Courtois Y, Behar-Cohen F. Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem. Biophys. Res. Commun. 295, 336-341 (2002) (Pubitemid 34785839)
120. Souied EH, Reid SNM, Piri NI, Lerner LE, Nusinowitz S, Farber DB. Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration. Exp. Eye Res. 87, 168-175 (2008)
121. Molokhia SA, Jeong EK, Higuchi WI, Li SK. Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp. Eye Res. 88, 418-425 (2009)
122. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest. Ophthalmol. Vis. Sci. 49, 320-332 (2008)
123. Balachandran RK, Barocas VH. Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow. Pharm. Res. 25, 2685-2696 (2008)
124. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection. J. Ocul. Pharmacol. Ther. 20, 43-53 (2004) (Pubitemid 38199331)
125. Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection. J. Ocul. Pharmacol. Ther. 25, 29-37 (2009)
126. Mac Gabhann F, Demetriades AM, Deering T et al. Protein transport to choroid and retina following periocular injection: theoretical and experimental study. Ann. Biomed. Eng. 35, 615-630 (2007) (Pubitemid 46448166)
127. Dias CS, Mitra AK. Vitreal elimination kinetics of large molecular weight FITC-labeled dextrans in albino rabbits using a novel microsampling technique. J. Pharm. Sci. 89, 572-578 (2000)
128. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR)Pharm. Res. 26, 1236-1260 (2009)
129. Cruysberg LP, Nuijts RM, Geroski DH, Gilbert JA, Hendrikse F, Edelhauser HF. The influence of intraocular pressure on the transscleral diffusion of high-molecular-weight compounds. Invest. Ophthalmol. Vis. Sci. 46, 3790-3794 (2005) (Pubitemid 44264687)
130. Shuler RK Jr, Dioguardi PK, Henjy C, Nickerson JM, Cruysberg LP, Edelhauser HF. Scleral permeability of a small, single-stranded oligonucleotide. J. Ocul. Pharmacol. Ther. 20, 159-168 (2004) (Pubitemid 38456589)
131. Ethier CR, Johnson M, Ruberti J. Ocular biomechanics and biotransport. Annu. Rev. Biomed. Eng. 6, 249-273 (2004) (Pubitemid 39209499)
132. Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci. 76, 583-586 (1987). (Pubitemid 18026341)